Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies

NCT01750983 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01750983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01750983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
February 21, 2019
Enrollment
101 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers